News

Filter

Current filters:

EnbrelKineret

1 to 9 of 16 results

RA biological competitors spent $195M on promotion

08-01-2007

The six companies with approved rheumatoid arthritis biologics in 2005 (Amgen, Wyeth, Centocor, Schering-Plough,…

AbataceptadalimumabAmgenAnakinraBristol-Myers SquibbEnbreletanerceptHumirainfliximabKineretOrenciaRemicadeSchering PloughSchering-PloughWyeth

Amgen unveils a promising R&D pipeline but investors remain uncertain

05-04-2004

The USA's Amgen presented its full R&D pipeline of potential drugs last week, but its shares slumped…

AmgenAnakinraAranespDarbepoetin AlfaEnbrelEpoetin AlfaEpogenetanerceptFilgrastimKineretNeulastaNeupogenpegfilgrastimProcritWyeth

Amgen names Willard Dere VP, and head of its inflammation therapeutic area

14-07-2003

Willard Dere, formerly a vice president with Eli Lily, has joined Amgen as vice president and head of…

AmgenAnakinraEnbreletanerceptKineret

Amgen's rheumatoid arthritis drug Kineret cleared for marketing in Europe

18-03-2002

Amgen's new therapy for rheumatoid arthritis, the interleukin-1receptor antagonist Kineret (anakinra),…

AmgenAnakinraAranespDarbepoetin AlfaEnbreletanerceptKineretmethotrexateNeulastapegfilgrastimTrexall

Amgen planning to acquire Immunex Corp in $18 billion deal?

07-01-2002

It has been reported that Amgen is in advanced negotiations to acquirefellow US biotechnology firm Immunex…

AmgenAnakinraEnbrelEpoetin AlfaEpogenetanerceptFilgrastimKineretNeupogenProcrit

Amgen's Kineret cleared in first market

16-11-2001

Amgen's interleukin-1 receptor antagonist Kineret (anakinra) has beenapproved in its first market, the…

AmgenAnakinraEnbreletanerceptinfliximabKineretRemicade

1 to 9 of 16 results

Back to top